Business
Issue of Equity
Issue of Equity.
About this update from Immupharma Plc
[{"type":"text","content":"\n \nRNS Number : 0304Q Immupharma PLC 24 February 2016 \n\n 24 FEBRUARY 2016\nImmuPharma PLC\n \nIssue of Equity\nSuccessful placing provides funding for completion of Phase III Lupuzor™ Trial\n \nImmuPharma PLC (LSE:IMM) (\"ImmuPharma\" or the \"Company\"), the specialist drug discovery and development company, is pleased to announce the issue and allotment of 30,302,217 new ordinary shares of 10 pence each (\"New Ordinary Shares\"), raising £7.7 million in connection with the Placing and Subscription, as announced on 5 February 2016 (the \"Placing and Subscription Announcement\").\nFurthermore, as outlined in the Placing and Subscription Announcement, the Company has applied to HM Revenue and Customs to receive VCT Advance Assurance and / or EIS Advance Assurance but, as of the date of this announcement, the Advance Assurances have not yet been received. The issue of any EIS Shares and the VCT Shares within the Placing, amounting to 2,856,539 Ordinary Shares which would raise a further £0.7 million for the Company (raising in aggregate £8.4 million, as announced in the Placing and Subscription Announcement), is conditional upon the Advance Assurances being obtained by not later than 23 March 2016. The Company intends to issue and allot the EIS Shares and VCT Shares provided the Advance Assurances are received by that date. A further update will be provided in due...